1.	Phase III Master Protocol for Randomized Comparison of Single-agent Chemotherapy vs Standard Therapy with CAF (CTX/DOX/5-FU) in Previously Untreated Patients with Stage IV Breast Carcinoma --- Amonafide and Other Phase II Agents Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 16 to physiologic 70 Sponsor: NCI Protocol IDs: CLB-8642, CALGB-8642
2.	Phase II Study with Elsamitrucin in Patients with Locally Advanced, Unresectable, or Metastatic Advanced Ovarian Carcinoma (Summary Last Modified 08/91) Phase: Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Protocol IDs: EORTC-16902O
3.	Phase II Study with Elsamitrucin in Patients with Locally Advanced, Unresectable, or Metastatic Breast Cancer (Summary Last Modified 07/91) Phase: Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Protocol IDs: EORTC-16902B
4.	Phase II Study with Elsamitrucin in Patients with Locally Advanced, Unresectable, or Metastatic Colorectal Cancer (Summary Last Modified 07/91) Phase: Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Protocol IDs: EORTC-16902C
5.	Phase II Study with Elsamitrucin in Patients with Locally Advanced, Unresectable, or Metastatic non-Small Cell Lung Cancer (Summary Last Modified 07/91) Phase: Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Protocol IDs: EORTC-16902L
6.	Phase II Study of Elsamitrucin in Patients with Unresectable or Metastatic Nonsmall Cell Lung Cancer (Summary Last Modified 10/92) Phase: Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Protocol IDs: CAN-NCIC-IND65, NCI-V92-0107, IND65
7.	Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ELSA 2004-001, NCT00090090
8.	Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 13NHL-04-1, NCT00184080